Instil Bio, Inc. (TIL) stock
TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.08−0.16 (-2.56%)
Close on Nov 13, 2026Market cap $41.23MP/E –Yield –
Instil Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Instil Bio's operating cash flow for the twelve months ending Sep 30, 2026 was -$15.46M. For fiscal 2025 it was -$36.62M. The highest annual figure on record is -$29.62M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.62M | – |
| FY2024 | Dec 31, 2024 | -$55.70M | – |
| FY2023 | Dec 31, 2023 | -$82.03M | – |
| FY2022 | Dec 31, 2022 | -$180.16M | – |
| FY2021 | Dec 31, 2021 | -$122.14M | – |
| FY2020 | Dec 31, 2020 | -$29.62M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.41M | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.43M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.66M | – |
| Q4 FY2022 | Dec 31, 2022 | -$36.98M | – |
| Q3 FY2022 | Sep 30, 2022 | -$40.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$47.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$55.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$42.79M | – |
| Q3 FY2021 | Sep 30, 2021 | -$29.40M | – |
| Q2 FY2021 | Jun 30, 2021 | -$32.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.82M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.28M | – |
See a number that looks wrong?